P27361
SS
Gene name |
MAPK3 (ERK1, PRKM3) |
Protein name |
Mitogen-activated protein kinase 3 |
Names |
MAP kinase 3 , MAPK 3 , EC 2.7.11.24 , ERT2 , Extracellular signal-regulated kinase 1 , ERK-1 , Insulin-stimulated MAP2 kinase , MAP kinase isoform p44 , p44-MAPK , Microtubule-associated protein 2 kinase , p44-ERK1 |
Species |
Homo sapiens (Human) |
KEGG Pathway |
hsa:5595 |
EC number |
2.7.11.24: Protein-serine/threonine kinases |
Protein Class |
|
Descriptions
MAPK1 encodes Mitogen-activated protein kinase 1, and is involved in diverse cellular responses by phosphorylating cytoplasmic and nuclear proteins. Unlike other MAP kinases, MAPK1 activates via dual phosphorylation of Thr-186 and Tyr-193 within the activation lip, and mutations at Q105 alone were sufficient for autoactivation. Additionally, in the inactive form, L76, Q10 and I87 form a structural unit that restrains intramolecular autophosphorylation by preventing interactions between activation lip residues and the catalytic base (D149) needed for phosphoryl transfer. Mutations at L76, I87 and additionally S153 increased basal specific activity via autophosphorylation of Thr-186 and Tyr-193.
Autoinhibitory domains (AIDs)
Target domain |
42-330 (Protein kinase domain) |
Relief mechanism |
PTM |
Assay |
|
Accessory elements
183-209 (Activation loop from InterPro)
Target domain |
42-330 (Protein kinase domain) |
Relief mechanism |
|
Assay |
|
References
- Emrick MA et al. (2006) "The gatekeeper residue controls autoactivation of ERK2 via a pathway of intramolecular connectivity", Proceedings of the National Academy of Sciences of the United States of America, 103, 18101-6
- Emrick MA et al. (2001) "Constitutive activation of extracellular signal-regulated kinase 2 by synergistic point mutations", The Journal of biological chemistry, 276, 46469-79
Autoinhibited structure
Activated structure
4 structures for P27361
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| 2ZOQ | X-ray | 239 A | A/B | 1-379 | PDB |
| 4QTB | X-ray | 140 A | A/B | 1-379 | PDB |
| 6GES | X-ray | 207 A | A/B | 1-379 | PDB |
| AF-P27361-F1 | Predicted | AlphaFoldDB |
486 variants for P27361
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs1186880470 | 2 | A>E | No | gnomAD | |
| rs1186880470 | 2 | A>G | No | gnomAD | |
| rs1186880470 | 2 | A>V | No | gnomAD | |
| rs1487093652 | 3 | A>E | No | gnomAD | |
| rs1487093652 | 3 | A>G | No | gnomAD | |
| rs2151048945 | 3 | A>T | No | Ensembl | |
| rs1487093652 | 3 | A>V | No | gnomAD | |
| rs1271627688 | 4 | A>E | No | gnomAD | |
| rs1271627688 | 4 | A>G | No | gnomAD | |
| rs1271627688 | 4 | A>V | No | gnomAD | |
| rs757216432 | 5 | A>G | No |
ExAC gnomAD |
|
| rs757216432 | 5 | A>V | No |
ExAC gnomAD |
|
| rs1203827432 | 6 | A>G | No | gnomAD | |
| rs753603085 | 6 | A>T | No |
ExAC TOPMed gnomAD |
|
| rs1464704515 | 7 | Q>E | No | gnomAD | |
| rs1267157456 | 7 | Q>L | No | gnomAD | |
| rs1267157456 | 7 | Q>P | No | gnomAD | |
| rs1267157456 | 7 | Q>R | No | gnomAD | |
| rs1275164140 | 8 | G>R | No |
TOPMed gnomAD |
|
| rs1275164140 | 8 | G>W | No |
TOPMed gnomAD |
|
| rs559183760 | 9 | G>A | No |
1000Genomes ExAC TOPMed gnomAD |
|
| rs559183760 | 9 | G>D | No |
1000Genomes ExAC TOPMed gnomAD |
|
| rs559183760 | 9 | G>V | No |
1000Genomes ExAC TOPMed gnomAD |
|
| rs2151048882 | 10 | G>E | No | Ensembl | |
| rs955881745 | 11 | G>A | No |
TOPMed gnomAD |
|
| rs2073036554 | 11 | G>C | No | gnomAD | |
| rs955881745 | 11 | G>V | No |
TOPMed gnomAD |
|
| rs767677001 | 12 | G>W | No |
ExAC gnomAD |
|
| rs1461921044 | 13 | E>* | No |
TOPMed gnomAD |
|
| rs2073036224 | 13 | E>A | No |
TOPMed gnomAD |
|
|
TCGA novel rs1031507615 |
13 | E>D | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
NCI-TCGA Ensembl |
| rs1461921044 | 13 | E>K | No |
TOPMed gnomAD |
|
| rs1461921044 | 13 | E>Q | No |
TOPMed gnomAD |
|
| rs759741789 | 14 | P>H | No |
ExAC gnomAD |
|
|
rs766922585 RCV000893252 |
15 | R>C | No |
ClinVar 1000Genomes ExAC TOPMed dbSNP gnomAD |
|
| rs1314762868 | 16 | R>G | No |
TOPMed gnomAD |
|
| rs2073035911 | 17 | T>I | No |
TOPMed gnomAD |
|
| rs1452164335 | 18 | E>D | No |
TOPMed gnomAD |
|
| rs1596884873 | 18 | E>G | No | Ensembl | |
|
COSM1301856 COSM4812189 COSM1301857 |
18 | E>Q | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs1468414653 | 19 | G>A | No | TOPMed | |
| rs1468414653 | 19 | G>E | No | TOPMed | |
| rs1468414653 | 19 | G>V | No | TOPMed | |
| rs2073035624 | 20 | V>A | No | gnomAD | |
| rs2073035669 | 20 | V>F | No | TOPMed | |
| rs2073035624 | 20 | V>G | No | gnomAD | |
| rs2073035669 | 20 | V>I | No | TOPMed | |
| rs773609716 | 21 | G>C | No |
ExAC TOPMed gnomAD |
|
| rs773609716 | 21 | G>S | No |
ExAC TOPMed gnomAD |
|
| rs770120964 | 22 | P>L | No |
ExAC TOPMed gnomAD |
|
| rs770120964 | 22 | P>R | No |
ExAC TOPMed gnomAD |
|
| rs1596884823 | 24 | V>A | No | Ensembl | |
| rs1596884823 | 24 | V>G | No | Ensembl | |
| rs2073035329 | 24 | V>I | No | Ensembl | |
| rs1338865633 | 24 | V>S | Variant assessed as Somatic; HIGH impact. [NCI-TCGA] | No | NCI-TCGA |
| rs2073035221 | 25 | P>L | No | TOPMed | |
| rs2073035221 | 25 | P>R | No | TOPMed | |
| rs1044163469 | 25 | P>S | No | TOPMed | |
| rs775053127 | 26 | G>E | No |
ExAC gnomAD |
|
| rs775053127 | 26 | G>V | No |
ExAC gnomAD |
|
| rs1372891365 | 27 | E>D | No | gnomAD | |
| rs1596884789 | 27 | E>G | No | Ensembl | |
| rs1302416785 | 27 | E>K | No | gnomAD | |
| rs868114863 | 28 | V>G | No | Ensembl | |
| rs1336432605 | 29 | E>G | No | TOPMed | |
| rs1326850245 | 30 | M>R | No | gnomAD | |
| rs1326850245 | 30 | M>T | No | gnomAD | |
| rs2073034798 | 30 | M>V | No | TOPMed | |
| rs375146669 | 31 | V>A | No |
ESP ExAC TOPMed gnomAD |
|
| rs375146669 | 31 | V>G | No |
ESP ExAC TOPMed gnomAD |
|
| rs1280565276 | 33 | G>E | No | TOPMed | |
| rs865801855 | 33 | G>W | No | gnomAD | |
| rs2073034611 | 34 | Q>* | No |
TOPMed gnomAD |
|
| rs2073034563 | 34 | Q>H | No | TOPMed | |
| rs2151048720 | 35 | P>S | No | Ensembl | |
| rs980128823 | 37 | D>E | No |
TOPMed gnomAD |
|
| rs2151048709 | 38 | V>E | No | Ensembl | |
| rs1394035337 | 38 | V>L | No |
TOPMed gnomAD |
|
| rs1394035337 | 38 | V>M | No |
TOPMed gnomAD |
|
| rs2073034354 | 39 | G>A | No | gnomAD | |
| rs1173425325 | 39 | G>C | No | gnomAD | |
| rs1173425325 | 39 | G>S | No | gnomAD | |
| rs755905535 | 40 | P>L | No |
ExAC TOPMed gnomAD |
|
| rs755905535 | 40 | P>Q | No |
ExAC TOPMed gnomAD |
|
| rs555123973 | 40 | P>S | No |
1000Genomes ExAC gnomAD |
|
| rs868133732 | 41 | R>C | No | Ensembl | |
| rs1437705688 | 41 | R>H | No | gnomAD | |
| rs1437705688 | 41 | R>L | No | gnomAD | |
| rs752945713 | 42 | Y>C | No |
ExAC gnomAD |
|
| rs781519812 | 43 | T>M | No |
ExAC TOPMed gnomAD |
|
| rs781519812 | 43 | T>R | No |
ExAC TOPMed gnomAD |
|
| rs755251449 | 44 | Q>* | No |
ExAC gnomAD |
|
| rs751628704 | 45 | L>F | No |
ExAC gnomAD |
|
| rs971370284 | 47 | Y>* | No | gnomAD | |
| rs2151048657 | 48 | I>M | No | Ensembl | |
| rs766621106 | 48 | I>T | No |
ExAC gnomAD |
|
| rs2073033788 | 48 | I>V | No | gnomAD | |
| rs2073033657 | 50 | E>* | No |
TOPMed gnomAD |
|
| rs2073033657 | 50 | E>Q | No |
TOPMed gnomAD |
|
| rs2151048642 | 52 | A>T | No | Ensembl | |
| rs1374312265 | 53 | Y>* | No |
TOPMed gnomAD |
|
| rs2151048638 | 53 | Y>C | No | Ensembl | |
| rs1313150757 | 54 | G>C | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
NCI-TCGA gnomAD |
| rs2151048629 | 54 | G>D | No | Ensembl | |
| rs1313150757 | 54 | G>S | No | gnomAD | |
| rs762034287 | 55 | M>L | No |
ExAC gnomAD |
|
| rs889768664 | 55 | M>R | No | gnomAD | |
|
rs889768664 RCV002247964 |
55 | M>T | No |
ClinVar dbSNP gnomAD |
|
| rs1157149769 | 56 | V>D | No | gnomAD | |
| rs1157149769 | 56 | V>G | No | gnomAD | |
| rs1024996900 | 56 | V>I | No | Ensembl | |
| rs1370684329 | 58 | S>* | No | gnomAD | |
|
TCGA novel COSM184937 rs1370684329 |
58 | S>L | Variant assessed as Somatic; MODERATE impact. large_intestine [NCI-TCGA, Cosmic] | No |
cosmic curated NCI-TCGA gnomAD |
| rs147961867 | 60 | Y>C | No |
1000Genomes ESP ExAC TOPMed gnomAD |
|
| rs2151047916 | 60 | Y>H | No | Ensembl | |
| rs200617125 | 63 | V>M | No |
1000Genomes ESP ExAC TOPMed gnomAD |
|
| rs753070820 | 64 | R>C | No |
ExAC TOPMed gnomAD |
|
| rs753070820 | 64 | R>G | No |
ExAC TOPMed gnomAD |
|
| rs1196812695 | 64 | R>H | No | TOPMed | |
| rs1196812695 | 64 | R>P | No | TOPMed | |
| rs2073020790 | 66 | T>N | No | TOPMed | |
| rs2073020790 | 66 | T>S | No | TOPMed | |
| rs567762331 | 67 | R>C | No |
1000Genomes ExAC TOPMed gnomAD |
|
| rs567762331 | 67 | R>G | No |
1000Genomes ExAC TOPMed gnomAD |
|
| rs772578869 | 67 | R>H | No |
ExAC TOPMed gnomAD |
|
| rs772578869 | 67 | R>L | No |
ExAC TOPMed gnomAD |
|
| rs567762331 | 67 | R>S | No |
1000Genomes ExAC TOPMed gnomAD |
|
| rs776770058 | 68 | V>M | No |
ExAC gnomAD |
|
| rs768729666 | 69 | A>D | No |
ExAC TOPMed gnomAD |
|
| rs2151047890 | 69 | A>T | No | Ensembl | |
| rs768729666 | 69 | A>V | No |
ExAC TOPMed gnomAD |
|
| rs775457072 | 70 | I>M | No |
ExAC gnomAD |
|
| rs746736375 | 70 | I>V | No |
ExAC gnomAD |
|
| rs2151047883 | 71 | K>E | No | Ensembl | |
| rs1483843681 | 74 | S>N | No | gnomAD | |
| rs1483843681 | 74 | S>T | No | gnomAD | |
| rs1277805136 | 75 | P>L | No | gnomAD | |
| rs772136444 | 76 | F>L | No |
ExAC TOPMed gnomAD |
|
| rs771108532 | 77 | E>D | No |
ExAC gnomAD |
|
|
COSM969785 rs778826879 COSM1588409 COSM4873717 |
77 | E>K | Variant assessed as Somatic; MODERATE impact. endometrium [NCI-TCGA, Cosmic] | No |
NCI-TCGA Cosmic cosmic curated ExAC NCI-TCGA gnomAD |
| rs778826879 | 77 | E>Q | No |
ExAC gnomAD |
|
| rs749779624 | 78 | H>Y | No |
ExAC TOPMed gnomAD |
|
| rs778192562 | 79 | Q>H | No |
ExAC TOPMed gnomAD |
|
| rs1596883447 | 80 | T>P | No | Ensembl | |
| rs1297705239 | 81 | Y>H | No | gnomAD | |
| rs756613927 | 82 | C>R | No |
ExAC TOPMed gnomAD |
|
| rs2151047840 | 82 | C>W | No | Ensembl | |
| rs781660515 | 84 | R>C | No |
ExAC gnomAD |
|
|
COSM4875436 COSM969783 COSM4875437 rs757959447 |
84 | R>H | Variant assessed as Somatic; MODERATE impact. endometrium [NCI-TCGA, Cosmic] | No |
NCI-TCGA Cosmic cosmic curated ExAC gnomAD |
| rs757959447 | 84 | R>L | No |
ExAC gnomAD |
|
|
TCGA novel rs1375850297 |
85 | T>M | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
NCI-TCGA TOPMed gnomAD |
| TCGA novel | 85 | T>missing | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs1375850297 | 85 | T>K | No |
TOPMed gnomAD |
|
| rs750160678 | 87 | R>G | No |
ExAC gnomAD |
|
| rs374549766 | 87 | R>Q | No |
ESP ExAC TOPMed gnomAD |
|
|
COSM3508758 rs750160678 COSM3508757 COSM3508756 |
87 | R>W | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
NCI-TCGA Cosmic ExAC NCI-TCGA gnomAD |
| rs1315743155 | 88 | E>K | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
NCI-TCGA TOPMed gnomAD |
| rs141047495 | 89 | I>V | No |
ESP ExAC TOPMed gnomAD |
|
| rs2073019201 | 91 | I>F | No | gnomAD | |
| rs1258517367 | 91 | I>M | No | TOPMed | |
| rs1209777305 | 92 | L>V | No | gnomAD | |
| rs760710625 | 93 | L>Q | No |
ExAC gnomAD |
|
|
COSM4857281 COSM471620 COSM4857282 rs1596883362 |
94 | R>C | kidney Variant assessed as Somatic; MODERATE impact. [Cosmic, NCI-TCGA] | No |
NCI-TCGA Cosmic cosmic curated Ensembl |
| rs1212630199 | 94 | R>H | No | gnomAD | |
| rs1212630199 | 94 | R>L | No | gnomAD | |
| rs771940747 | 96 | R>C | No |
ExAC TOPMed gnomAD |
|
| rs771940747 | 96 | R>G | No |
ExAC TOPMed gnomAD |
|
| rs2151047779 | 96 | R>H | No | Ensembl | |
| rs2151047779 | 96 | R>L | No | Ensembl | |
| rs1229544781 | 97 | H>L | No | gnomAD | |
| rs2151047778 | 98 | E>K | No | Ensembl | |
| rs759671938 | 100 | V>I | No |
ExAC gnomAD |
|
|
COSM3508754 COSM3508755 COSM3508753 |
102 | G>D | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs1291454132 | 102 | G>R | No |
TOPMed gnomAD |
|
| rs1291454132 | 102 | G>S | No |
TOPMed gnomAD |
|
| rs2151047765 | 103 | I>T | No | Ensembl | |
| rs774690695 | 104 | R>P | No |
ExAC TOPMed |
|
| rs774690695 | 104 | R>Q | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
ExAC NCI-TCGA TOPMed |
| rs972865611 | 105 | D>E | No | TOPMed | |
| rs1555487522 | 106 | I>L | No | Ensembl | |
| rs771152806 | 108 | R>Q | No |
ExAC gnomAD |
|
| rs1414402131 | 108 | R>W | No | gnomAD | |
| rs749295922 | 109 | A>S | No |
ExAC TOPMed gnomAD |
|
| rs1159823467 | 111 | T>A | No |
TOPMed gnomAD |
|
| rs2073018251 | 111 | T>I | No | Ensembl | |
| rs1159823467 | 111 | T>P | No |
TOPMed gnomAD |
|
| rs969998383 | 112 | L>P | No | gnomAD | |
| rs976845326 | 113 | E>K | No |
TOPMed gnomAD |
|
| rs61736373 | 114 | A>G | No |
ESP ExAC TOPMed gnomAD |
|
| rs61736373 | 114 | A>V | No |
ESP ExAC TOPMed gnomAD |
|
| rs945368057 | 120 | I>T | No |
TOPMed gnomAD |
|
| rs767419781 | 120 | I>V | No |
ExAC gnomAD |
|
| rs1312251788 | 121 | V>L | No | Ensembl | |
| rs751316636 | 135 | S>R | No |
ExAC gnomAD |
|
| TCGA novel | 136 | Q>H | Variant assessed as Somatic; HIGH impact. [NCI-TCGA] | No | NCI-TCGA |
| rs2151045986 | 137 | Q>* | No | Ensembl | |
| rs1272004454 | 137 | Q>R | No | TOPMed | |
| rs1194104997 | 138 | L>R | No | gnomAD | |
| rs921399991 | 140 | N>S | No |
TOPMed gnomAD |
|
| rs2151045975 | 141 | D>E | No | Ensembl | |
| rs2151045979 | 141 | D>Y | No | Ensembl | |
| rs1275674122 | 142 | H>R | No |
TOPMed gnomAD |
|
|
COSM4060086 COSM4060087 COSM4060085 |
148 | Y>C | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs1596880314 | 151 | L>P | No | Ensembl | |
| rs1302344555 | 152 | R>P | No | gnomAD | |
| rs1302344555 | 152 | R>Q | No | gnomAD | |
|
COSM4813329 COSM1478780 rs2151045957 COSM435101 |
152 | R>W | Variant assessed as Somatic; MODERATE impact. breast [NCI-TCGA, Cosmic] | No |
NCI-TCGA Cosmic cosmic curated Ensembl |
| rs2072982035 | 153 | G>D | No | TOPMed | |
| rs2072981973 | 154 | L>F | No | TOPMed | |
| rs2151045948 | 154 | L>P | No | Ensembl | |
| rs1596880292 | 156 | Y>F | No | Ensembl | |
| rs1596880292 | 156 | Y>S | No | Ensembl | |
| rs369434621 | 157 | I>F | No |
ESP ExAC TOPMed gnomAD |
|
| rs1434947666 | 158 | H>L | No | Ensembl | |
| rs761888725 | 158 | H>Y | No |
ExAC gnomAD |
|
| rs2151045938 | 159 | S>F | No | Ensembl | |
| rs747519025 | 160 | A>G | No |
ExAC TOPMed gnomAD |
|
| rs769159731 | 160 | A>P | No |
ExAC gnomAD |
|
|
rs769159731 COSM5028120 COSM5028121 COSM5028122 |
160 | A>T | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
NCI-TCGA Cosmic ExAC NCI-TCGA gnomAD |
| rs747519025 | 160 | A>V | No |
ExAC TOPMed gnomAD |
|
| rs1374038009 | 161 | N>S | No | gnomAD | |
| TCGA novel | 161 | N>T | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs1430679556 | 162 | V>L | No |
TOPMed gnomAD |
|
| rs1430679556 | 162 | V>M | No |
TOPMed gnomAD |
|
| rs2151045926 | 163 | L>F | No | Ensembl | |
| rs1170802161 | 164 | H>P | No | TOPMed | |
| rs966226222 | 164 | H>Q | No | Ensembl | |
| rs2151045922 | 164 | H>Y | No | Ensembl | |
| rs1173483036 | 165 | R>* | No |
TOPMed gnomAD |
|
| rs1173483036 | 165 | R>G | No |
TOPMed gnomAD |
|
| rs1379935159 | 165 | R>L | No |
TOPMed gnomAD |
|
| rs1379935159 | 165 | R>P | No |
TOPMed gnomAD |
|
| rs1379935159 | 165 | R>Q | No |
TOPMed gnomAD |
|
| rs1248034366 | 167 | L>V | No |
TOPMed gnomAD |
|
| rs2151045901 | 169 | P>S | No | Ensembl | |
| TCGA novel | 170 | S>F | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs1180252391 | 171 | N>I | No | gnomAD | |
| rs2151045896 | 171 | N>K | No | Ensembl | |
| rs1252612325 | 173 | L>P | No | gnomAD | |
| rs1472345530 | 173 | L>V | No | gnomAD | |
| rs191342631 | 175 | N>S | No |
1000Genomes ExAC gnomAD |
|
| rs191342631 | 175 | N>T | No |
1000Genomes ExAC gnomAD |
|
| rs2072980852 | 177 | T>A | No | TOPMed | |
| rs61736375 | 178 | C>* | No |
1000Genomes ExAC gnomAD |
|
| rs2072980814 | 179 | D>H | No | gnomAD | |
|
COSM5384715 COSM5384714 rs2072980814 COSM5384716 |
179 | D>N | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
NCI-TCGA Cosmic gnomAD |
| rs2151045854 | 179 | D>V | No | Ensembl | |
|
COSM1301852 COSM1301853 COSM4811168 |
182 | I>N | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs759912582 | 182 | I>V | No |
ExAC gnomAD |
|
| rs2072978710 | 183 | C>S | No | Ensembl | |
| rs538281952 | 186 | G>A | No | Ensembl | |
| rs538281952 | 186 | G>D | No | Ensembl | |
| rs2072978578 | 186 | G>S | No |
TOPMed gnomAD |
|
| rs2151045706 | 188 | A>T | No | Ensembl | |
| rs747800465 | 188 | A>V | No |
ExAC gnomAD |
|
| rs780719391 | 189 | R>G | No |
ExAC gnomAD |
|
| rs768111899 | 189 | R>L | No |
ExAC TOPMed gnomAD |
|
|
COSM1241412 rs768111899 COSM1241413 |
189 | R>Q | oesophagus [Cosmic] | No |
cosmic curated ExAC TOPMed gnomAD |
| rs780719391 | 189 | R>W | No |
ExAC gnomAD |
|
| rs2072978252 | 190 | I>M | No | TOPMed | |
| rs1416421966 | 191 | A>T | No |
TOPMed gnomAD |
|
| rs868745990 | 191 | A>V | No | Ensembl | |
| rs1284498604 | 192 | D>N | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
NCI-TCGA gnomAD |
| rs1449756762 | 192 | D>V | No | gnomAD | |
| rs2151045685 | 194 | E>D | No | Ensembl | |
| rs2151045687 | 194 | E>V | No | Ensembl | |
| rs758366759 | 195 | H>L | No |
ExAC gnomAD |
|
| rs758366759 | 195 | H>R | No |
ExAC gnomAD |
|
| rs2072977786 | 195 | H>Y | No | TOPMed | |
| rs2151045678 | 196 | D>E | No | Ensembl | |
| rs2151045674 | 197 | H>Y | No | Ensembl | |
| rs1159063202 | 198 | T>I | No | TOPMed | |
| rs2072977632 | 198 | T>P | No | TOPMed | |
| rs1159063202 | 198 | T>S | No | TOPMed | |
| rs1335287328 | 199 | G>A | No | gnomAD | |
| rs1335287328 | 199 | G>D | No | gnomAD | |
| rs1435051948 | 199 | G>S | No | gnomAD | |
| rs1389956626 | 201 | L>P | No | gnomAD | |
| rs1321995174 | 202 | T>M | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
NCI-TCGA TOPMed gnomAD |
| rs1321995174 | 202 | T>R | No |
TOPMed gnomAD |
|
| rs1596879875 | 204 | Y>D | No | Ensembl | |
| rs2072977152 | 205 | V>G | No | gnomAD | |
| rs2151045646 | 206 | A>G | No | Ensembl | |
| rs200652640 | 207 | T>K | No |
TOPMed gnomAD |
|
| rs200652640 | 207 | T>M | No |
TOPMed gnomAD |
|
|
TCGA novel rs2072977004 |
208 | R>C | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
NCI-TCGA TOPMed gnomAD |
| rs754076411 | 208 | R>H | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
ExAC NCI-TCGA TOPMed gnomAD |
| rs754076411 | 208 | R>P | No |
ExAC TOPMed gnomAD |
|
| rs2072976961 | 209 | W>* | No | gnomAD | |
| rs1596879860 | 210 | Y>D | No | Ensembl | |
| rs1473863224 | 210 | Y>S | No |
TOPMed gnomAD |
|
| rs1187651122 | 211 | R>L | No |
TOPMed gnomAD |
|
| rs1187651122 | 211 | R>Q | No |
TOPMed gnomAD |
|
| rs764219989 | 211 | R>W | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
ExAC NCI-TCGA TOPMed gnomAD |
| rs1249867970 | 215 | I>L | No |
TOPMed gnomAD |
|
| rs1441994509 | 215 | I>N | No |
TOPMed gnomAD |
|
| rs1441994509 | 215 | I>T | No |
TOPMed gnomAD |
|
| rs1249867970 | 215 | I>V | No |
TOPMed gnomAD |
|
| rs1289903922 | 220 | K>N | No | gnomAD | |
| rs2151045607 | 220 | K>R | No | Ensembl | |
| rs61764216 | 221 | G>= | Variant assessed as Somatic; LOW impact. [NCI-TCGA] | No | NCI-TCGA |
| rs763165244 | 224 | K>N | No |
ExAC TOPMed gnomAD |
|
| rs1567355024 | 224 | K>R | No | Ensembl | |
| rs1425849315 | 225 | S>C | No | gnomAD | |
| rs773660441 | 226 | I>V | No |
ExAC TOPMed gnomAD |
|
|
TCGA novel rs2072972785 |
227 | D>N | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
NCI-TCGA TOPMed gnomAD |
| rs1208471014 | 228 | I>V | No | TOPMed | |
| rs1289763589 | 231 | V>M | No |
TOPMed gnomAD |
|
| rs981009203 | 232 | G>A | No |
TOPMed gnomAD |
|
| rs981009203 | 232 | G>V | No |
TOPMed gnomAD |
|
| rs1277248636 | 233 | C>Y | No | gnomAD | |
| rs774952017 | 240 | S>C | No |
ExAC gnomAD |
|
| rs1287735708 | 242 | R>P | No | gnomAD | |
| rs1287735708 | 242 | R>Q | No | gnomAD | |
| rs745793573 | 242 | R>W | No |
ExAC gnomAD |
|
| rs2072972056 | 243 | P>R | No | TOPMed | |
| rs1187527463 | 246 | P>S | No |
TOPMed gnomAD |
|
| rs2072971859 | 248 | K>R | No |
TOPMed gnomAD |
|
| rs1567354917 | 249 | H>R | No | Ensembl | |
| rs1405884583 | 255 | N>S | No | TOPMed | |
| rs1465396263 | 258 | L>M | No | gnomAD | |
| rs1359519711 | 258 | L>P | No | gnomAD | |
| rs1596879030 | 259 | G>D | No | Ensembl | |
| rs1596879030 | 259 | G>V | No | Ensembl | |
| rs2151045141 | 260 | I>M | No | Ensembl | |
| rs898931255 | 262 | G>D | No | Ensembl | |
| rs2072966610 | 262 | G>S | No |
TOPMed gnomAD |
|
| rs2151045130 | 263 | S>F | No | Ensembl | |
| rs2151045125 | 265 | S>F | No | Ensembl | |
| rs1436855694 | 265 | S>P | No | TOPMed | |
| rs2072966500 | 267 | E>K | No |
TOPMed gnomAD |
|
| rs2151045124 | 268 | D>G | No | Ensembl | |
| rs1388847305 | 268 | D>N | No | gnomAD | |
|
COSM969781 COSM4873607 COSM1588410 |
269 | L>P | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs2151045116 | 271 | C>F | No | Ensembl | |
| rs749294480 | 272 | I>V | No |
ExAC TOPMed gnomAD |
|
| TCGA novel | 273 | I>M | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs1017891903 | 273 | I>V | No |
TOPMed gnomAD |
|
| rs2072966240 | 275 | M>V | No |
TOPMed gnomAD |
|
| rs2151045105 | 277 | A>G | No | Ensembl | |
| rs772848887 | 277 | A>P | No |
ExAC gnomAD |
|
| rs769773760 | 278 | R>* | Variant assessed as Somatic; HIGH impact. [NCI-TCGA] | No |
ExAC NCI-TCGA gnomAD |
| rs2072966140 | 278 | R>P | No | TOPMed | |
|
rs2072966140 TCGA novel |
278 | R>Q | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
NCI-TCGA TOPMed |
| rs1263696399 | 279 | N>K | No | gnomAD | |
| rs1244338832 | 280 | Y>H | No | gnomAD | |
| rs2151045092 | 282 | Q>* | No | Ensembl | |
| rs2151045089 | 282 | Q>H | No | Ensembl | |
| rs748363746 | 284 | L>V | No |
ExAC gnomAD |
|
| rs1037434377 | 285 | P>S | No |
TOPMed gnomAD |
|
| rs1225959995 | 286 | S>C | No | gnomAD | |
| rs1225959995 | 286 | S>F | No | gnomAD | |
| rs781501542 | 286 | S>T | No |
ExAC gnomAD |
|
| rs1225959995 | 286 | S>Y | No | gnomAD | |
| rs1567354680 | 287 | K>E | No | Ensembl | |
| rs1596878949 | 288 | T>I | No | Ensembl | |
| rs1596878949 | 288 | T>S | No | Ensembl | |
| rs1364153026 | 289 | K>N | No |
TOPMed gnomAD |
|
| COSM282662 | 290 | V>A | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs755286262 | 290 | V>M | No |
ExAC TOPMed gnomAD |
|
| rs747014104 | 291 | A>D | No |
ExAC gnomAD |
|
| rs747014104 | 291 | A>G | No |
ExAC gnomAD |
|
| rs1437119658 | 291 | A>T | No | gnomAD | |
| rs1458119852 | 292 | W>* | No | gnomAD | |
| rs758801293 | 293 | A>G | No |
ExAC gnomAD |
|
| rs2151045061 | 293 | A>T | No | Ensembl | |
| rs758801293 | 293 | A>V | No |
ExAC gnomAD |
|
| rs2151045059 | 294 | K>N | No | Ensembl | |
| rs751006818 | 295 | L>F | No |
ExAC TOPMed gnomAD |
|
| rs2151045053 | 295 | L>P | No | Ensembl | |
| rs866972428 | 297 | P>L | No | Ensembl | |
| rs866972428 | 297 | P>R | No | Ensembl | |
| rs2072965521 | 299 | S>L | No | TOPMed | |
| rs2151045042 | 299 | S>T | No | Ensembl | |
| rs11546680 | 300 | D>A | No |
ExAC TOPMed gnomAD |
|
| rs11546680 | 300 | D>G | No |
ExAC TOPMed gnomAD |
|
| rs11546680 | 300 | D>V | No |
ExAC TOPMed gnomAD |
|
| rs757561553 | 301 | S>P | No |
ExAC TOPMed gnomAD |
|
| rs2072965398 | 302 | K>* | No | Ensembl | |
| rs754204507 | 302 | K>R | No |
ExAC TOPMed gnomAD |
|
|
COSM3508741 COSM3508742 rs1393537562 COSM3508743 |
303 | A>V | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
NCI-TCGA Cosmic NCI-TCGA gnomAD |
| rs1172563462 | 304 | L>F | No |
TOPMed gnomAD |
|
| TCGA novel | 304 | L>P | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs1172563462 | 304 | L>V | No |
TOPMed gnomAD |
|
| rs975482399 | 305 | D>E | No |
TOPMed gnomAD |
|
| rs1472294951 | 307 | L>M | No | gnomAD | |
| rs1019644388 | 309 | R>L | No |
TOPMed gnomAD |
|
| rs1019644388 | 309 | R>Q | No |
TOPMed gnomAD |
|
| rs762464616 | 309 | R>W | No |
ExAC TOPMed gnomAD |
|
| rs749988410 | 310 | M>I | No |
ExAC gnomAD |
|
| rs1596878691 | 310 | M>T | No | Ensembl | |
|
COSM4858512 COSM4858513 COSM703308 |
314 | N>I | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs2151044881 | 315 | P>H | No | Ensembl | |
| rs2072963012 | 315 | P>S | No | gnomAD | |
| rs752551671 | 318 | R>Q | No |
ExAC TOPMed gnomAD |
|
|
COSM1678993 rs755904687 COSM1678994 |
318 | R>W | Variant assessed as Somatic; MODERATE impact. haematopoietic_and_lymphoid_tissue [NCI-TCGA, Cosmic] | No |
NCI-TCGA Cosmic cosmic curated ExAC NCI-TCGA TOPMed gnomAD |
| rs2072962836 | 320 | T>A | No | TOPMed | |
| rs2072962801 | 321 | V>A | No | TOPMed | |
| rs2072962767 | 322 | E>Q | No | TOPMed | |
| rs896753662 | 323 | E>D | No | TOPMed | |
|
VAR_042253 rs55859133 RCV000891817 |
323 | E>K | No |
ClinVar UniProt 1000Genomes ESP ExAC TOPMed dbSNP gnomAD |
|
| rs2151044859 | 324 | A>S | No | Ensembl | |
| rs1329197803 | 324 | A>V | No |
TOPMed gnomAD |
|
| rs2151044854 | 325 | L>Q | No | Ensembl | |
| rs1339088523 | 326 | A>G | No |
TOPMed gnomAD |
|
| rs775725620 | 326 | A>P | No |
ExAC gnomAD |
|
| rs775725620 | 326 | A>S | No |
ExAC gnomAD |
|
| rs775725620 | 326 | A>T | No |
ExAC gnomAD |
|
| rs766518304 | 327 | H>N | No |
ExAC TOPMed gnomAD |
|
| rs1596878619 | 327 | H>P | No | Ensembl | |
| rs766518304 | 327 | H>Y | No |
ExAC TOPMed gnomAD |
|
| rs1167791407 | 328 | P>S | No | gnomAD | |
| TCGA novel | 328 | P>T | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs2072962102 | 329 | Y>C | No | Ensembl | |
| rs778983958 | 330 | L>V | No |
ExAC TOPMed gnomAD |
|
| rs2151044835 | 331 | E>D | No | Ensembl | |
| rs202207118 | 331 | E>Q | No |
ESP ExAC TOPMed gnomAD |
|
| rs2072961975 | 332 | Q>E | No | TOPMed | |
| rs1250178194 | 335 | D>E | No |
TOPMed gnomAD |
|
|
COSM3794790 COSM3794791 COSM3794789 |
335 | D>N | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs778102867 | 336 | P>L | No |
ExAC TOPMed gnomAD |
|
| rs749833759 | 336 | P>S | No |
ExAC TOPMed gnomAD |
|
| rs527481960 | 337 | T>K | No |
ExAC TOPMed gnomAD |
|
| rs527481960 | 337 | T>M | No |
ExAC TOPMed gnomAD |
|
| rs527481960 | 337 | T>R | No |
ExAC TOPMed gnomAD |
|
| rs2151044813 | 338 | D>H | No | Ensembl | |
| rs61736376 | 339 | E>K | No | Ensembl | |
| rs2151044811 | 339 | E>V | No | Ensembl | |
| rs2151044673 | 340 | P>S | No | Ensembl | |
| rs764055195 | 341 | V>A | No |
ExAC TOPMed gnomAD |
|
| rs764055195 | 341 | V>E | No |
ExAC TOPMed gnomAD |
|
| rs2151044669 | 341 | V>M | No | Ensembl | |
| rs2151044666 | 342 | A>T | No | Ensembl | |
| rs752512625 | 343 | E>* | No |
ExAC TOPMed gnomAD |
|
| rs1182054221 | 343 | E>D | No |
TOPMed gnomAD |
|
| rs752512625 | 343 | E>K | No |
ExAC TOPMed gnomAD |
|
| rs752512625 | 343 | E>Q | No |
ExAC TOPMed gnomAD |
|
| rs2151044661 | 344 | E>D | No | Ensembl | |
| rs2151044659 | 345 | P>A | No | Ensembl | |
| rs2072958196 | 347 | T>I | No | Ensembl | |
| rs1330587787 | 347 | T>P | No | gnomAD | |
| rs1330587787 | 347 | T>S | No | gnomAD | |
| rs774610689 | 349 | A>G | No |
ExAC gnomAD |
|
| rs759750021 | 349 | A>P | No |
ExAC gnomAD |
|
| rs759750021 | 349 | A>S | No |
ExAC gnomAD |
|
|
rs759750021 TCGA novel |
349 | A>T | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
NCI-TCGA ExAC gnomAD |
| rs774610689 | 349 | A>V | No |
ExAC gnomAD |
|
| rs762951234 | 350 | M>V | No |
ExAC gnomAD |
|
| rs2072958011 | 351 | E>Q | No | gnomAD | |
| rs773193659 | 353 | D>G | No |
ExAC TOPMed gnomAD |
|
| rs2072957938 | 353 | D>Y | No | Ensembl | |
| rs770315722 | 354 | D>A | No |
ExAC TOPMed gnomAD |
|
| rs2072957824 | 354 | D>E | No | TOPMed | |
| rs2072957793 | 355 | L>V | No | Ensembl | |
| rs141882258 | 356 | P>S | No |
ESP ExAC TOPMed gnomAD |
|
| rs777053157 | 359 | R>G | No |
ExAC TOPMed gnomAD |
|
|
COSM6144430 COSM6144429 |
359 | R>L | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs1246728652 | 359 | R>Q | No |
TOPMed gnomAD |
|
|
rs777053157 COSM3402266 COSM99215 |
359 | R>W | Variant assessed as Somatic; MODERATE impact. central_nervous_system stomach [NCI-TCGA, Cosmic] | No |
NCI-TCGA Cosmic cosmic curated ExAC NCI-TCGA TOPMed gnomAD |
| rs1427624736 | 360 | L>V | No | TOPMed | |
| rs778643863 | 362 | E>D | No |
ExAC gnomAD |
|
|
COSM3508731 rs747392494 COSM3508730 |
362 | E>K | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
NCI-TCGA Cosmic ExAC NCI-TCGA TOPMed gnomAD |
| rs912617565 | 363 | L>F | No | gnomAD | |
| rs2151044620 | 363 | L>P | No | Ensembl | |
| rs2072957442 | 364 | I>F | No | TOPMed | |
| rs2072957442 | 364 | I>V | No | TOPMed | |
|
COSM1286093 COSM1286094 |
367 | E>D | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs1308413252 | 367 | E>G | No |
TOPMed gnomAD |
|
| rs2151044617 | 368 | T>P | No | Ensembl | |
| rs2072957305 | 369 | A>G | No | TOPMed | |
| rs2072957305 | 369 | A>V | No | TOPMed | |
| rs756047833 | 370 | R>C | No |
ExAC TOPMed gnomAD |
|
| rs376745934 | 370 | R>H | No |
ESP ExAC TOPMed gnomAD |
|
| rs376745934 | 370 | R>P | No |
ESP ExAC TOPMed gnomAD |
|
| rs756047833 | 370 | R>S | No |
ExAC TOPMed gnomAD |
|
| rs986826212 | 371 | F>C | No | gnomAD | |
| rs2151044597 | 372 | Q>* | No | Ensembl | |
| rs754705731 | 372 | Q>R | No |
ExAC TOPMed gnomAD |
|
| rs1274257423 | 373 | P>L | No |
TOPMed gnomAD |
|
| rs751357233 | 373 | P>S | No |
ExAC gnomAD |
|
| rs751357233 | 373 | P>T | No |
ExAC gnomAD |
|
| rs372149021 | 374 | G>R | No |
ESP ExAC TOPMed gnomAD |
|
| rs765303927 | 378 | A>D | No |
ExAC TOPMed gnomAD |
|
| rs765303927 | 378 | A>V | No |
ExAC TOPMed gnomAD |
|
| rs776945868 | 380 | P>W | No |
ExAC TOPMed gnomAD |
|
| rs1193845457 | 380 | P>Y | No |
TOPMed gnomAD |
No associated diseases with P27361
4 regional properties for P27361
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | Protein kinase domain | 42 - 330 | IPR000719 |
| conserved_site | Mitogen-activated protein (MAP) kinase, conserved site | 76 - 178 | IPR003527 |
| active_site | Serine/threonine-protein kinase, active site | 162 - 174 | IPR008271 |
| binding_site | Protein kinase, ATP binding site | 48 - 72 | IPR017441 |
Functions
| Description | ||
|---|---|---|
| EC Number | 2.7.11.24 | Protein-serine/threonine kinases |
| Subcellular Localization |
|
|
| PANTHER Family | ||
| PANTHER Subfamily | ||
| PANTHER Protein Class | ||
| PANTHER Pathway Category | No pathway information available | |
16 GO annotations of cellular component
| Name | Definition |
|---|---|
| caveola | A membrane raft that forms small pit, depression, or invagination that communicates with the outside of a cell and extends inward, indenting the cytoplasm and the cell membrane. Examples include flask-shaped invaginations of the plasma membrane in adipocytes associated with caveolin proteins, and minute pits or incuppings of the cell membrane formed during pinocytosis. Caveolae may be pinched off to form free vesicles within the cytoplasm. |
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| cytoskeleton | A cellular structure that forms the internal framework of eukaryotic and prokaryotic cells. The cytoskeleton includes intermediate filaments, microfilaments, microtubules, the microtrabecular lattice, and other structures characterized by a polymeric filamentous nature and long-range order within the cell. The various elements of the cytoskeleton not only serve in the maintenance of cellular shape but also have roles in other cellular functions, including cellular movement, cell division, endocytosis, and movement of organelles. |
| cytosol | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. |
| early endosome | A membrane-bounded organelle that receives incoming material from primary endocytic vesicles that have been generated by clathrin-dependent and clathrin-independent endocytosis; vesicles fuse with the early endosome to deliver cargo for sorting into recycling or degradation pathways. |
| endoplasmic reticulum lumen | The volume enclosed by the membranes of the endoplasmic reticulum. |
| focal adhesion | A cell-substrate junction that anchors the cell to the extracellular matrix and that forms a point of termination of actin filaments. In insects focal adhesion has also been referred to as hemi-adherens junction (HAJ). |
| glutamatergic synapse | A synapse that uses glutamate as a neurotransmitter. |
| Golgi apparatus | A membrane-bound cytoplasmic organelle of the endomembrane system that further processes the core oligosaccharides (e.g. N-glycans) added to proteins in the endoplasmic reticulum and packages them into membrane-bound vesicles. The Golgi apparatus operates at the intersection of the secretory, lysosomal, and endocytic pathways. |
| late endosome | A prelysosomal endocytic organelle differentiated from early endosomes by lower lumenal pH and different protein composition. Late endosomes are more spherical than early endosomes and are mostly juxtanuclear, being concentrated near the microtubule organizing center. |
| mitochondrion | A semiautonomous, self replicating organelle that occurs in varying numbers, shapes, and sizes in the cytoplasm of virtually all eukaryotic cells. It is notably the site of tissue respiration. |
| nuclear envelope | The double lipid bilayer enclosing the nucleus and separating its contents from the rest of the cytoplasm; includes the intermembrane space, a gap of width 20-40 nm (also called the perinuclear space). |
| nucleoplasm | That part of the nuclear content other than the chromosomes or the nucleolus. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
| plasma membrane | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. |
| pseudopodium | A temporary protrusion or retractile process of a cell, associated with flowing movements of the protoplasm, and serving for locomotion and feeding. |
8 GO annotations of molecular function
| Name | Definition |
|---|---|
| ATP binding | Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator. |
| DNA-binding transcription factor binding | Binding to a DNA-binding transcription factor, a protein that interacts with a specific DNA sequence (sometimes referred to as a motif) within the regulatory region of a gene to modulate transcription. |
| identical protein binding | Binding to an identical protein or proteins. |
| MAP kinase activity | Catalysis of the reaction |
| phosphatase binding | Binding to a phosphatase. |
| phosphotyrosine residue binding | Binding to a phosphorylated tyrosine residue within a protein. |
| protein serine kinase activity | Catalysis of the reactions |
| protein serine/threonine kinase activity | Catalysis of the reactions |
55 GO annotations of biological process
| Name | Definition |
|---|---|
| apoptotic process | A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. |
| Bergmann glial cell differentiation | The process in which neuroepithelial cells of the neural tube give rise to Brgmann glial cells, specialized bipotential progenitors cells of the cerebellum. Differentiation includes the processes involved in commitment of a cell to a specific fate. |
| BMP signaling pathway | The series of molecular signals initiated by the binding of a member of the BMP (bone morphogenetic protein) family to a receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. |
| cardiac neural crest cell development involved in heart development | The process aimed at the progression of a cardiac neural crest cell over time, from initial commitment of the cell to its specific fate, to the fully functional differentiated cell that contributes to the development of the heart. |
| cartilage development | The process whose specific outcome is the progression of a cartilage element over time, from its formation to the mature structure. Cartilage elements are skeletal elements that consist of connective tissue dominated by extracellular matrix containing collagen type II and large amounts of proteoglycan, particularly chondroitin sulfate. |
| caveolin-mediated endocytosis | An endocytosis process that begins when material is taken up into plasma membrane caveolae, which then pinch off to form endocytic caveolar carriers. |
| cell cycle | The progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication events. Canonically, the cell cycle comprises the replication and segregation of genetic material followed by the division of the cell, but in endocycles or syncytial cells nuclear replication or nuclear division may not be followed by cell division. |
| cellular response to amino acid starvation | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of amino acids. |
| cellular response to cadmium ion | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cadmium (Cd) ion stimulus. |
| cellular response to mechanical stimulus | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a mechanical stimulus. |
| cellular response to reactive oxygen species | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a reactive oxygen species stimulus. Reactive oxygen species include singlet oxygen, superoxide, and oxygen free radicals. |
| cellular response to tumor necrosis factor | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tumor necrosis factor stimulus. |
| DNA-templated transcription | The synthesis of an RNA transcript from a DNA template. |
| ERBB2-ERBB3 signaling pathway | The series of molecular signals initiated by binding of a ligand to a ERBB3 receptor on the surface of a cell, followed by transmission of the signal by a heterodimeric complex of ERBB2 and ERBB3. ERBB2, which does not bind any known ligand, is activated through formation of a heterodimer with another ligand-activated ERBB family member such as ERBB3. ERBB3 also has impaired kinase activity and relies on ERBB2 for activation and signal transmission. |
| ERK1 and ERK2 cascade | An intracellular protein kinase cascade containing at least ERK1 or ERK2 (MAPKs), a MEK (a MAPKK) and a MAP3K. The cascade may involve 4 different kinases, as it can also contain an additional tier |
| face development | The biological process whose specific outcome is the progression of a face from an initial condition to its mature state. The face is the ventral division of the head. |
| insulin receptor signaling pathway | The series of molecular signals generated as a consequence of the insulin receptor binding to insulin. |
| insulin-like growth factor receptor signaling pathway | The series of molecular signals initiated by a ligand binding to an insulin-like growth factor receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. |
| interleukin-1-mediated signaling pathway | The series of molecular signals initiated by interleukin-1 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. |
| intracellular signal transduction | The process in which a signal is passed on to downstream components within the cell, which become activated themselves to further propagate the signal and finally trigger a change in the function or state of the cell. |
| lipopolysaccharide-mediated signaling pathway | The series of molecular signals initiated by the binding of a lipopolysaccharide (LPS) to a receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. Lipopolysaccharides are major components of the outer membrane of Gram-negative bacteria, making them prime targets for recognition by the immune system. |
| lung morphogenesis | The process in which the anatomical structures of the lung are generated and organized. |
| MAPK cascade | An intracellular protein kinase cascade containing at least a MAPK, a MAPKK and a MAP3K. The cascade can also contain an additional tiers |
| modulation of chemical synaptic transmission | Any process that modulates the frequency or amplitude of synaptic transmission, the process of communication from a neuron to a target (neuron, muscle, or secretory cell) across a synapse. Amplitude, in this case, refers to the change in postsynaptic membrane potential due to a single instance of synaptic transmission. |
| myelination | The process in which myelin sheaths are formed and maintained around neurons. Oligodendrocytes in the brain and spinal cord and Schwann cells in the peripheral nervous system wrap axons with compact layers of their plasma membrane. Adjacent myelin segments are separated by a non-myelinated stretch of axon called a node of Ranvier. |
| negative regulation of TORC1 signaling | Any process that stops, prevents or reduces the frequency, rate or extent of TORC1 signaling. |
| outer ear morphogenesis | The process in which the anatomical structures of the outer ear are generated and organized. The outer ear is the part of the ear external to the tympanum (eardrum). It consists of a tube (the external auditory meatus) that directs sound waves on to the tympanum, and may also include the external pinna, which extends beyond the skull. |
| peptidyl-tyrosine autophosphorylation | The phosphorylation by a protein of one or more of its own tyrosine amino acid residues, or a tyrosine residue on an identical protein. |
| phosphorylation | The process of introducing a phosphate group into a molecule, usually with the formation of a phosphoric ester, a phosphoric anhydride or a phosphoric amide. |
| positive regulation of cyclase activity | Any process that activates or increases the activity of a cyclase. |
| positive regulation of ERK1 and ERK2 cascade | Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade. |
| positive regulation of macrophage chemotaxis | Any process that increases the rate, frequency or extent of macrophage chemotaxis. Macrophage chemotaxis is the movement of a macrophage in response to an external stimulus. |
| positive regulation of macrophage proliferation | Any process that activates or increases the frequency, rate or extent of macrophage proliferation. |
| positive regulation of telomerase activity | Any process that activates or increases the frequency, rate or extent of telomerase activity, the catalysis of the reaction |
| positive regulation of telomere capping | Any process that activates or increases the frequency, rate or extent of telomere capping. |
| positive regulation of telomere maintenance via telomerase | Any process that activates or increases the frequency, rate or extent of the addition of telomeric repeats by telomerase. |
| positive regulation of transcription by RNA polymerase II | Any process that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter. |
| positive regulation of xenophagy | Any process that activates or increases the frequency, rate or extent of xenophagy. |
| protein phosphorylation | The process of introducing a phosphate group on to a protein. |
| regulation of cellular pH | Any process involved in the maintenance of an internal equilibrium of hydrogen ions (protons) within a cell or between a cell and its external environment. |
| regulation of cytoskeleton organization | Any process that modulates the frequency, rate or extent of the formation, arrangement of constituent parts, or disassembly of cytoskeletal structures. |
| regulation of early endosome to late endosome transport | Any process that modulates the frequency, rate or extent of early endosome to late endosome transport. |
| regulation of Golgi inheritance | Any process that modulates the rate, frequency or extent of Golgi inheritance. Golgi inheritance is the partitioning of Golgi apparatus between daughter cells at cell division. |
| regulation of ossification | Any process that modulates the frequency, rate or extent of ossification, the formation of bone or of a bony substance or the conversion of fibrous tissue or of cartilage into bone or a bony substance. |
| regulation of stress-activated MAPK cascade | Any process that modulates the frequency, rate or extent of signal transduction mediated by the stress-activated MAPK cascade. |
| response to epidermal growth factor | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an epidermal growth factor stimulus. |
| response to exogenous dsRNA | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an exogenous double-stranded RNA stimulus. |
| Schwann cell development | The process aimed at the progression of a Schwann cell over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell. Schwann cells are found in the peripheral nervous system, where they insulate neurons and axons, and regulate the environment in which neurons function. |
| sensory perception of pain | The series of events required for an organism to receive a painful stimulus, convert it to a molecular signal, and recognize and characterize the signal. Pain is medically defined as the physical sensation of discomfort or distress caused by injury or illness, so can hence be described as a harmful stimulus which signals current (or impending) tissue damage. Pain may come from extremes of temperature, mechanical damage, electricity or from noxious chemical substances. This is a neurological process. |
| signal transduction in response to DNA damage | A cascade of processes induced by the detection of DNA damage within a cell. |
| stress-activated MAPK cascade | The series of molecular signals in which a stress-activated MAP kinase cascade relays a signal; MAP kinase cascades involve at least three protein kinase activities and culminate in the phosphorylation and activation of a MAP kinase. |
| thymus development | The process whose specific outcome is the progression of the thymus over time, from its formation to the mature structure. The thymus is a symmetric bi-lobed organ involved primarily in the differentiation of immature to mature T cells, with unique vascular, nervous, epithelial, and lymphoid cell components. |
| thyroid gland development | The process whose specific outcome is the progression of the thyroid gland over time, from its formation to the mature structure. The thyroid gland is an endoderm-derived gland that produces thyroid hormone. |
| trachea formation | The process pertaining to the initial formation of a trachea from unspecified parts. The process begins with the specific processes that contribute to the appearance of the discrete structure and ends when the trachea is recognizable. The trachea is the portion of the airway that attaches to the bronchi as it branches. |
| xenophagy | The selective autophagy process in which a region of cytoplasm containing an intracellular pathogen or some part of an intracellular pathogen (e.g. viral capsid) is enclosed in a double membrane bound autophagosome, which then fuses with the lysosome leading to degradation of the contents. |
92 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| P16892 | FUS3 | Mitogen-activated protein kinase FUS3 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast) | SS |
| P14681 | KSS1 | Mitogen-activated protein kinase KSS1 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast) | SS |
| A5PKJ4 | MAPK7 | Mitogen-activated protein kinase 7 | Bos taurus (Bovine) | SS |
| Q3T0N5 | MAPK13 | Mitogen-activated protein kinase 13 | Bos taurus (Bovine) | SS |
| P46196 | MAPK1 | Mitogen-activated protein kinase 1 | Bos taurus (Bovine) | SS |
| Q5F3W3 | MAPK6 | Mitogen-activated protein kinase 6 | Gallus gallus (Chicken) | SS |
| Q95NE7 | MAPK14 | Mitogen-activated protein kinase 14 | Pan troglodytes (Chimpanzee) | SS |
| Q9N272 | MAPK13 | Mitogen-activated protein kinase 13 | Pan troglodytes (Chimpanzee) | SS |
| Q9W354 | Erk7 | Extracellular signal-regulated kinase 7 | Drosophila melanogaster (Fruit fly) | SS |
| O61443 | p38b | Mitogen-activated protein kinase p38b | Drosophila melanogaster (Fruit fly) | SS |
| O62618 | p38a | Mitogen-activated protein kinase p38a | Drosophila melanogaster (Fruit fly) | SS |
| P83100 | p38c | Putative mitogen-activated protein kinase 14C | Drosophila melanogaster (Fruit fly) | SS |
| P40417 | rl | Mitogen-activated protein kinase ERK-A | Drosophila melanogaster (Fruit fly) | SS |
| P20794 | MAK | Serine/threonine-protein kinase MAK | Homo sapiens (Human) | PR |
| Q9UQ07 | MOK | MAPK/MAK/MRK overlapping kinase | Homo sapiens (Human) | PR |
| Q8TD08 | MAPK15 | Mitogen-activated protein kinase 15 | Homo sapiens (Human) | SS |
| P45984 | MAPK9 | Mitogen-activated protein kinase 9 | Homo sapiens (Human) | SS |
| P45983 | MAPK8 | Mitogen-activated protein kinase 8 | Homo sapiens (Human) | EV |
| P53779 | MAPK10 | Mitogen-activated protein kinase 10 | Homo sapiens (Human) | EV |
| Q9UBE8 | NLK | Serine/threonine-protein kinase NLK | Homo sapiens (Human) | SS |
| P28482 | MAPK1 | Mitogen-activated protein kinase 1 | Homo sapiens (Human) | EV |
| P31152 | MAPK4 | Mitogen-activated protein kinase 4 | Homo sapiens (Human) | SS |
| Q16659 | MAPK6 | Mitogen-activated protein kinase 6 | Homo sapiens (Human) | SS |
| Q13164 | MAPK7 | Mitogen-activated protein kinase 7 | Homo sapiens (Human) | SS |
| P53778 | MAPK12 | Mitogen-activated protein kinase 12 | Homo sapiens (Human) | SS |
| O15264 | MAPK13 | Mitogen-activated protein kinase 13 | Homo sapiens (Human) | SS |
| Q15759 | MAPK11 | Mitogen-activated protein kinase 11 | Homo sapiens (Human) | SS |
| Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Homo sapiens (Human) | SS |
| Q9Z1B7 | Mapk13 | Mitogen-activated protein kinase 13 | Mus musculus (Mouse) | SS |
| P47811 | Mapk14 | Mitogen-activated protein kinase 14 | Mus musculus (Mouse) | SS |
| Q61532 | Mapk6 | Mitogen-activated protein kinase 6 | Mus musculus (Mouse) | SS |
| Q9WVS8 | Mapk7 | Mitogen-activated protein kinase 7 | Mus musculus (Mouse) | SS |
| Q9WUI1 | Mapk11 | Mitogen-activated protein kinase 11 | Mus musculus (Mouse) | SS |
| O08911 | Mapk12 | Mitogen-activated protein kinase 12 | Mus musculus (Mouse) | SS |
| Q80Y86 | Mapk15 | Mitogen-activated protein kinase 15 | Mus musculus (Mouse) | SS |
| Q6P5G0 | Mapk4 | Mitogen-activated protein kinase 4 | Mus musculus (Mouse) | SS |
| P63085 | Mapk1 | Mitogen-activated protein kinase 1 | Mus musculus (Mouse) | SS |
| Q63844 | Mapk3 | Mitogen-activated protein kinase 3 | Mus musculus (Mouse) | SS |
| P70618 | Mapk14 | Mitogen-activated protein kinase 14 | Rattus norvegicus (Rat) | SS |
| Q9WTY9 | Mapk13 | Mitogen-activated protein kinase 13 | Rattus norvegicus (Rat) | SS |
| Q9Z2A6 | Mapk15 | Mitogen-activated protein kinase 15 | Rattus norvegicus (Rat) | SS |
| P27704 | Mapk6 | Mitogen-activated protein kinase 6 | Rattus norvegicus (Rat) | SS |
| Q63538 | Mapk12 | Mitogen-activated protein kinase 12 | Rattus norvegicus (Rat) | SS |
| Q63454 | Mapk4 | Mitogen-activated protein kinase 4 | Rattus norvegicus (Rat) | SS |
| P0C865 | Mapk7 | Mitogen-activated protein kinase 7 | Rattus norvegicus (Rat) | SS |
| P63086 | Mapk1 | Mitogen-activated protein kinase 1 | Rattus norvegicus (Rat) | SS |
| P21708 | Mapk3 | Mitogen-activated protein kinase 3 | Rattus norvegicus (Rat) | SS |
| Q5ZCI1 | MPK10 | Mitogen-activated protein kinase 10 | Oryza sativa subsp. japonica (Rice) | SS |
| Q5VP69 | MPK16 | Mitogen-activated protein kinase 16 | Oryza sativa subsp. japonica (Rice) | SS |
| Q5SN53 | MPK8 | Mitogen-activated protein kinase 8 | Oryza sativa subsp. japonica (Rice) | SS |
| Q0E459 | MPK13 | Mitogen-activated protein kinase 13 | Oryza sativa subsp. japonica (Rice) | SS |
| Q75KK8 | MPK14 | Mitogen-activated protein kinase 14 | Oryza sativa subsp. japonica (Rice) | SS |
| Q67C40 | MPK7 | Mitogen-activated protein kinase 7 | Oryza sativa subsp. japonica (Rice) | SS |
| Q6L5F7 | MPK17 | Mitogen-activated protein kinase 17 | Oryza sativa subsp. japonica (Rice) | SS |
| Q5VN19 | MPK11 | Mitogen-activated protein kinase 11 | Oryza sativa subsp. japonica (Rice) | SS |
| Q5Z9J0 | MPK12 | Mitogen-activated protein kinase 12 | Oryza sativa subsp. japonica (Rice) | SS |
| Q53N72 | MPK15 | Mitogen-activated protein kinase 15 | Oryza sativa subsp. japonica (Rice) | SS |
| Q5Z859 | MPK4 | Mitogen-activated protein kinase 4 | Oryza sativa subsp. japonica (Rice) | SS |
| Q6Z437 | MPK3 | Mitogen-activated protein kinase 3 | Oryza sativa subsp. japonica (Rice) | SS |
| Q336X9 | MPK6 | Mitogen-activated protein kinase 6 | Oryza sativa subsp. japonica (Rice) | SS |
| Q5J4W4 | MPK2 | Mitogen-activated protein kinase 2 | Oryza sativa subsp. japonica (Rice) | SS |
| Q84UI5 | MPK1 | Mitogen-activated protein kinase 1 | Oryza sativa subsp. japonica (Rice) | SS |
| Q10N20 | MPK5 | Mitogen-activated protein kinase 5 | Oryza sativa subsp. japonica (Rice) | SS |
| Q17446 | pmk-1 | Mitogen-activated protein kinase pmk-1 | Caenorhabditis elegans | SS |
| Q11179 | mapk-15 | Mitogen-activated protein kinase 15 | Caenorhabditis elegans | SS |
| Q8MXI4 | pmk-2 | Mitogen-activated protein kinase pmk-2 | Caenorhabditis elegans | SS |
| O44514 | pmk-3 | Mitogen-activated protein kinase pmk-3 | Caenorhabditis elegans | PR |
| G5EBT1 | sma-5 | Mitogen-activated protein kinase sma-5 | Caenorhabditis elegans | SS |
| P39745 | mpk-1 | Mitogen-activated protein kinase mpk-1 | Caenorhabditis elegans | SS |
| Q9C9U4 | MPK15 | Mitogen-activated protein kinase 15 | Arabidopsis thaliana (Mouse-ear cress) | SS |
| Q9LV37 | MPK9 | Mitogen-activated protein kinase 9 | Arabidopsis thaliana (Mouse-ear cress) | SS |
| O23236 | MPK14 | Mitogen-activated protein kinase 14 | Arabidopsis thaliana (Mouse-ear cress) | SS |
| Q39021 | MPK1 | Mitogen-activated protein kinase 1 | Arabidopsis thaliana (Mouse-ear cress) | SS |
| Q39022 | MPK2 | Mitogen-activated protein kinase 2 | Arabidopsis thaliana (Mouse-ear cress) | SS |
| Q39027 | MPK7 | Mitogen-activated protein kinase 7 | Arabidopsis thaliana (Mouse-ear cress) | SS |
| Q84M93 | MPK17 | Mitogen-activated protein kinase 17 | Arabidopsis thaliana (Mouse-ear cress) | SS |
| Q8W4J2 | MPK16 | Mitogen-activated protein kinase 16 | Arabidopsis thaliana (Mouse-ear cress) | SS |
| Q9C5C0 | MPK18 | Mitogen-activated protein kinase 18 | Arabidopsis thaliana (Mouse-ear cress) | SS |
| Q9LM33 | MPK8 | Mitogen-activated protein kinase 8 | Arabidopsis thaliana (Mouse-ear cress) | SS |
| Q9LUC3 | MPK19 | Mitogen-activated protein kinase 19 | Arabidopsis thaliana (Mouse-ear cress) | SS |
| Q9SJG9 | MPK20 | Mitogen-activated protein kinase 20 | Arabidopsis thaliana (Mouse-ear cress) | SS |
| Q39023 | MPK3 | Mitogen-activated protein kinase 3 | Arabidopsis thaliana (Mouse-ear cress) | SS |
| Q39026 | MPK6 | Mitogen-activated protein kinase 6 | Arabidopsis thaliana (Mouse-ear cress) | SS |
| Q39025 | MPK5 | Mitogen-activated protein kinase 5 | Arabidopsis thaliana (Mouse-ear cress) | SS |
| Q39024 | MPK4 | Mitogen-activated protein kinase 4 | Arabidopsis thaliana (Mouse-ear cress) | SS |
| Q9M1Z5 | MPK10 | Mitogen-activated protein kinase 10 | Arabidopsis thaliana (Mouse-ear cress) | SS |
| Q8GYQ5 | MPK12 | Mitogen-activated protein kinase 12 | Arabidopsis thaliana (Mouse-ear cress) | SS |
| Q9LMM5 | MPK11 | Mitogen-activated protein kinase 11 | Arabidopsis thaliana (Mouse-ear cress) | SS |
| Q9LQQ9 | MPK13 | Mitogen-activated protein kinase 13 | Arabidopsis thaliana (Mouse-ear cress) | SS |
| O42376 | mapk12 | Mitogen-activated protein kinase 12 | Danio rerio (Zebrafish) (Brachydanio rerio) | SS |
| Q9DGE1 | mapk14b | Mitogen-activated protein kinase 14B | Danio rerio (Zebrafish) (Brachydanio rerio) | SS |
| Q9DGE2 | mapk14a | Mitogen-activated protein kinase 14A | Danio rerio (Zebrafish) (Brachydanio rerio) | SS |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MAAAAAQGGG | GGEPRRTEGV | GPGVPGEVEM | VKGQPFDVGP | RYTQLQYIGE | GAYGMVSSAY |
| 70 | 80 | 90 | 100 | 110 | 120 |
| DHVRKTRVAI | KKISPFEHQT | YCQRTLREIQ | ILLRFRHENV | IGIRDILRAS | TLEAMRDVYI |
| 130 | 140 | 150 | 160 | 170 | 180 |
| VQDLMETDLY | KLLKSQQLSN | DHICYFLYQI | LRGLKYIHSA | NVLHRDLKPS | NLLINTTCDL |
| 190 | 200 | 210 | 220 | 230 | 240 |
| KICDFGLARI | ADPEHDHTGF | LTEYVATRWY | RAPEIMLNSK | GYTKSIDIWS | VGCILAEMLS |
| 250 | 260 | 270 | 280 | 290 | 300 |
| NRPIFPGKHY | LDQLNHILGI | LGSPSQEDLN | CIINMKARNY | LQSLPSKTKV | AWAKLFPKSD |
| 310 | 320 | 330 | 340 | 350 | 360 |
| SKALDLLDRM | LTFNPNKRIT | VEEALAHPYL | EQYYDPTDEP | VAEEPFTFAM | ELDDLPKERL |
| 370 | |||||
| KELIFQETAR | FQPGVLEAP |